The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Deborah StephensFollowing recent changes to the NCCN guidelines®, the Lymphoma Hub was pleased to speak to Deborah Stephens, Huntsman Cancer Institute, Utah, US. We asked, What are the key updates to the NCCN guidelines® for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia?
What are the key updates to the NCCN guidelines® for CLL/SLL?
Stephens explains that the Bruton’s tyrosine kinase inhibitor, ibrutinib, has been moved from the ‘preferred regimens’ category to the ‘other recommended regimens’ category for patients with CLL. This was based on findings from the phase III ALPINE (NCT03734016) and ELEVATE-RR (NCT02477696) clinical trials, which demonstrated equal or better efficacy and reduced toxicity for zanubrutinib and acalabrutinib, respectively, compared with ibrutinib for relapsed/refractory CLL.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
